Tourmaline Bio Investor Relations Material
Latest events
Study Update
Tourmaline Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tourmaline Bio Inc
Access all reports
Tourmaline Bio Inc. is a biotechnology company focused on developing treatments for immune and inflammatory diseases. The company is engaged in the late-stage clinical development of therapies aimed at significantly improving the lives of patients with severe autoimmune and inflammatory conditions. Its product pipeline includes medicines designed to address conditions such as atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
TRML
Country
🇺🇸 United States